BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 26604862)

  • 1. Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research.
    Newman SK; Jayanthan RK; Mitchell GW; Carreras Tartak JA; Croglio MP; Suarez A; Liu AY; Razzo BM; Oyeniran E; Ruth JR; Fajgenbaum DC
    Yale J Biol Med; 2015 Dec; 88(4):383-8. PubMed ID: 26604862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of Castleman disease.
    Dispenzieri A; Fajgenbaum DC
    Blood; 2020 Apr; 135(16):1353-1364. PubMed ID: 32106302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease.
    Nabel CS; Sameroff S; Shilling D; Alapat D; Ruth JR; Kawano M; Sato Y; Stone K; Spetalen S; Valdivieso F; Feldman MD; Chadburn A; Fosså A; van Rhee F; Lipkin WI; Fajgenbaum DC
    PLoS One; 2019; 14(6):e0218660. PubMed ID: 31242229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.
    Fajgenbaum DC; van Rhee F; Nabel CS
    Blood; 2014 May; 123(19):2924-33. PubMed ID: 24622327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Bertinchamp R; Terriou L
    Rev Med Interne; 2022 Dec; 43(10S1):10S4-10S9. PubMed ID: 36657941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria.
    Zhang L; Dong YJ; Peng HL; Li H; Zhang MZ; Wang HH; Liu QH; Su LP; Zhong LY; Wu WJ; Huang L; Yan XJ; Fan L; Tang WJ; Li ZL; Bi LT; Li Y; Gao GX; Gao L; Liu TB; Wei YQ; Liu Y; Yu L; Zhou H; Sun CY; Qian WB; Zou DH; Zhang HL; Ding KY; Wang XB; Bai O; Huang WR; Chen B; Yang L; Song J; Gao D; Chen T; Luo J; Wang SY; Ma LM; Fajgenbaum DC; Li J;
    Lancet Reg Health West Pac; 2023 May; 34():100720. PubMed ID: 37283978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
    van Rhee F; Oksenhendler E; Srkalovic G; Voorhees P; Lim M; Dispenzieri A; Ide M; Parente S; Schey S; Streetly M; Wong R; Wu D; Maillard I; Brandstadter J; Munshi N; Bowne W; Elenitoba-Johnson KS; Fössa A; Lechowicz MJ; Chandrakasan S; Pierson SK; Greenway A; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Chadburn A; Fajgenbaum DC
    Blood Adv; 2020 Dec; 4(23):6039-6050. PubMed ID: 33284946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From Castleman disease histopathological features to idiopathic multicentric Castleman disease: a multiparametric approach to exclude potential iMCD histopathological mimickers.
    Rodriguez Merino L; Pomares AA; Arce JR; Montes-Moreno S
    J Clin Pathol; 2024 Apr; 77(5):318-323. PubMed ID: 36690434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The full spectrum of Castleman disease: 273 patients studied over 20 years.
    Oksenhendler E; Boutboul D; Fajgenbaum D; Mirouse A; Fieschi C; Malphettes M; Vercellino L; Meignin V; Gérard L; Galicier L
    Br J Haematol; 2018 Jan; 180(2):206-216. PubMed ID: 29143319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicentric Castlemans disease. Symptoms, diagnostics and therapy.
    Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Sandecká V; Krejčí M; Štork M; Ševčíková S; Král Z
    Vnitr Lek; 2022; 68(1):41-53. PubMed ID: 35459346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.
    Srkalovic G; Marijanovic I; Srkalovic MB; Fajgenbaum DC
    Bosn J Basic Med Sci; 2017 May; 17(2):81-84. PubMed ID: 28135567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recent advances in diagnosis and treatment of idiopathic multicentric Castleman disease].
    Okamoto S
    Rinsho Ketsueki; 2019; 60(9):1205-1211. PubMed ID: 31597845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease.
    Van Nieuwenhove E; Humblet-Baron S; Van Eyck L; De Somer L; Dooley J; Tousseyn T; Hershfield M; Liston A; Wouters C
    Pediatrics; 2018 Sep; 142(3):. PubMed ID: 30139808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman-like lymphadenopathies: A 20-year retrospective analysis of clinical and pathological features.
    Pelliccia S; Rogges E; Cardoni A; Lopez G; Conte E; Faccini AL; De Vito R; Girardi K; Bianchi A; Annibali O; Fratoni S; Remotti D; De Angelis G; Giordano C; Palumbo G; Scarpino S; Del Porto F; Bianchi MP; Di Gregorio F; Tafuri A; Di Napoli A
    Br J Haematol; 2024 Feb; 204(2):534-547. PubMed ID: 37953489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
    Fajgenbaum DC; Uldrick TS; Bagg A; Frank D; Wu D; Srkalovic G; Simpson D; Liu AY; Menke D; Chandrakasan S; Lechowicz MJ; Wong RS; Pierson S; Paessler M; Rossi JF; Ide M; Ruth J; Croglio M; Suarez A; Krymskaya V; Chadburn A; Colleoni G; Nasta S; Jayanthan R; Nabel CS; Casper C; Dispenzieri A; Fosså A; Kelleher D; Kurzrock R; Voorhees P; Dogan A; Yoshizaki K; van Rhee F; Oksenhendler E; Jaffe ES; Elenitoba-Johnson KS; Lim MS
    Blood; 2017 Mar; 129(12):1646-1657. PubMed ID: 28087540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
    Yu L; Tu M; Cortes J; Xu-Monette ZY; Miranda RN; Zhang J; Orlowski RZ; Neelapu S; Boddu PC; Akosile MA; Uldrick TS; Yarchoan R; Medeiros LJ; Li Y; Fajgenbaum DC; Young KH
    Blood; 2017 Mar; 129(12):1658-1668. PubMed ID: 28100459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms.
    Fraticelli S; Lucioni M; Neri G; Marchiori D; Cristinelli C; Merli M; Monaco R; Borra T; Lazzaro A; Uccella S; Arcaini L; Paulli M
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and management of Castleman disease.
    Soumerai JD; Sohani AR; Abramson JS
    Cancer Control; 2014 Oct; 21(4):266-78. PubMed ID: 25310208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.